-

04:05:06 AM

AMGN Stock News

AMGN - AMGEN Inc.

06/20/22 9:00 AM

Nasdaq : AMGN

AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM

The Amgen Foundation today announced an increased commitment to LabXchange, an online science education platform that provides users

RHEA-AI

neutral

06/10/22 4:15 PM

Nasdaq : AMGN

AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43 rd Annual Healthcare Conference at 1:40 p.m. ET on Wednesday, June 15, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive

RHEA-AI

neutral

06/06/22 9:00 AM

Nasdaq : AMGN

fda approval

FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a

RHEA-AI

positive

06/05/22 8:00 AM

Nasdaq : AMGN

NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER

Amgen (NASDAQ:AMGN) and

RHEA-AI

neutral

06/03/22 4:00 PM

Nasdaq : AMGN

AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday, June 8, 2022. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present at the conference. The webcast

RHEA-AI

neutral

05/31/22 9:00 AM

Nasdaq : AMGN

clinical trial

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical

RHEA-AI

neutral

05/26/22 5:00 PM

Nasdaq : AMGN

NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022

Results From the PARADIGM Phase 3 Head-to-Head Trial of Vectibix ® (panitumumab) Versus Bevacizumab in Untreated RAS Wild-Type Metastatic Colorectal Cancer*Largest Evaluation of Acquired Resistance to LUMAKRAS ® /LUMYKRAS ® (sotorasib) in KRAS G12C-mutated Cancers Inform Combination Treatment

RHEA-AI

neutral

05/12/22 8:00 AM

Nasdaq : AMGN

partnership

AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS

Amgen (NASDAQ:AMGN) and Otezla ® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign

RHEA-AI

neutral

05/06/22 4:00 PM

Nasdaq : AMGN

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m. ET on Wednesday, May 11, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice

RHEA-AI

neutral

05/02/22 9:00 AM

Nasdaq : AMGN

AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT

Amgen (NASDAQ:AMGN) today released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world.To view the Multimedia News Release,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

AMGN Data

Websitewww.amgen.com
CeoRobert Bradway
Security nameAMGEN Inc.
Issue typecs
Sic code2836
Employees24300
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address1 Amgen Center Dr
StateCalifornia
CityThousand Oaks
Zip91320-1799
CountryUS
Phone18054471000

About AMGEN Inc.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.